Previous Article | Next Article ![]()
Journal of Clinical Microbiology, June 2004, p. 2796-2798, Vol. 42, No. 6
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.6.2796-2798.2004
and John Nawrocki
Department of Infectious Disease and Department of Laboratory Medicine and Pathology, Edward Hines Jr. Veterans Administration Hospital, Hines, Illinois
Received 25 November 2003/ Returned for modification 10 January 2004/ Accepted 16 March 2004
|
|
|---|
|
|
|---|
Throat swab and nasal swab specimens were collected for influenza diagnosis during the course of routine patient care at the Edward Hines Jr. Veterans Administration Hospital in the winter of 1999 to 2000. Specimens were processed and tested with a Directigen Flu A kit (Becton Dickinson, Cockeysville, Md.) with subsequent viral isolation performed with specimens with a negative result. Specimens were subjected to RT-PCR using RNA isolated (with a QIAamp kit) from 100 µl of each specimen and of positive and negative controls. Eukaryotic RNA (300 ng) was spiked into each sample as an internal control for RNA degradation by the coamplification of ß2-microglobulin. cDNA was synthesized (at 42°C for 60 min) in a standard 20-µl reaction mixture containing 11 µl of each RNA preparation, 20 U of RT (Seikagaku America, East Falmouth, Mass.), and 1 µg of random primers (Pharmacia, Piscataway, N.J.). Mock reaction mixtures were run without RT (contamination control). PCR was performed with 50-µl reaction mixtures coamplifying the 212-bp segment of the influenza virus matrix gene (forward primer, 5'-CAGAGACTTGAAGATGTCTTTGCTG; reverse primer, 5'-GCTCTGTCCATGTTATTTGGATC) (3) and a 300-bp segment of the control ß2-microglobulin gene (forward primer, 5'-GCCTGCCGTGTGAACCACGTGAC; reverse primer, 5'-TACCTGTGGAGCAACCTGCTCAGA) (11). Each reaction mixture contained 10 µl of either the cDNA or mock cDNA reaction mixture for each specimen and 40 µl of a master mix containing 0.5 U of Taq polymerase (Applied Biosystems, Foster City, Calif.), 2.5 mM (each) dATP, dCTP, and dGTP, 5.0 mM dUTP (Pharmacia), 4 mM MgCl2, a 1.5 µM concentration of each PCR primer, and 0.5 U of Amperase (Applied Biosystems). A positive and negative control for the master mix was included with each assay. The cycling parameters were 50°C for 5 min; 94°C for 10 min; and 36 cycles of 94°C for 10 s, 54°C for 30 s, and 72°C for 30 s. To detect PCR products, 20 µl of each RT-PCR product was incubated at 37°C for 15 min with 20 µl of an internal matrix gene probe (5'-TCCTGTCACCTCTGACTAAGGGGATTTTG) end labeled with [
-32P]ATP (Amersham) (3). PCR products and size markers (Promega, Madison, Wis.) were separated on 0.8% agarose gels, which were subsequently stained with ethidium bromide for the direct detection of PCR products on a transilluminator. The gels were then exposed to X-ray film for 24 to 48 h, and influenza virus PCR products were detected by autoradiography. Results were deemed valid only if they met the following control conditions: detection of the ß2-microglobulin PCR product in the specimen cDNA reaction mixtures (for the RNA extraction control), no detection of PCR products in the mock cDNA or negative control reaction mixture (for the DNA contamination controls), and detection of PCR products in the low- and high-positive influenza virus control mixtures (for the sensitivity controls).
To detect amantadine- and rimantadine-resistant influenza A virus, the RT-PCR was performed as described above using specific cycling conditions (50°C for 5 min; 94°C for 10 min; and 42 cycles of 45°C for 1 min, 72°C for 1 min, and 94°C for 30 s) and primers (forward primer, 5'-GGGACTCATCCTAGCTCCAGTGCTGGTCTAAA; reverse primer, 5'-CGATCAAGAATCCACAATATCAAGTGCAAGATCCCAATAATA) (4, 9). A 164-bp segment that contained nucleotide changes resulting in amino acid substitutions at positions 26, 27, 30, and 31 of the M2 protein (2, 7) was amplified. Restriction fragment length polymorphism analysis of the amplified products was used to detect mutations at the four different positions as follows: AciI for position 26 (where wild-type DNA is digested), BspWI for position 27 (where mutant DNA is digested), ItaI for position 30 (where wild-type DNA is digested), and SspI for position 31 (where mutant DNA is digested). Digested products were analyzed by agarose gel electrophoresis as described above.
The assay was specific for influenza A virus (H1N1 and H3N2 subtypes) with a sensitivity of 5,000 copies/ml by gel staining or 50 copies/ml by autoradiography (data not shown). Of the 119 specimens collected, 29 (24%) were positive by Directigen Flu A, 0 were positive by shell vial assay, 6 were positive by tissue culture, and 56 (47%) were positive by RT-PCR. All specimens that were positive by RT-PCR were also positive by Directigen Flu A and/or viral isolation. A typical RT-PCR assay is shown in Fig. 1.
![]() View larger version (74K): [in a new window] |
FIG. 1. RT-PCR detection of influenza A virus by direct observation of ethidium-stained PCR products (top) and by autoradiography (bottom). Results are shown for influenza virus-negative (N) and -positive (P) controls and for patient samples 1 to 4. , mock RT reaction mixtures; +, reaction mixtures containing RT. Molecular weight markers are shown for the top panel. The upper band is the 300-bp ß2-microglobulin PCR product, and the lower band is the 212-bp influenza A virus PCR product.
|
![]() View larger version (100K): [in a new window] |
FIG. 2. Detection of amantadine resistance mutations at amino acid positions 30 (top) and 31 (bottom) by using restriction fragment length polymorphism of RT-PCR products. Results are shown for wild-type (Wild) and mutant control viruses and for patient samples (Pt.) 1 to 4. Undigested PCR products are shown in the left lane of each doublet. The right lane of each doublet shows the results of digesting PCR products with either ItaI (top) or SspI (bottom).
|
We are grateful for the help of Alexander I. Klimov from the Centers for Disease Control and Prevention, who provided us with the amantadine-resistant isolates of influenza A virus.
Present address: Stafford Creek Corrections Center, Aberdeen, Wash. ![]()
Present address: Division of LaboratoriesMolecular Biology, Illinois Department of Public Health, Chicago, Ill. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»